


## Maximum Diversification Portfolio & Risk Factor Exposure

LJLVTTF- Jan 2014



## Introduction

In this note we analyse the benefits of the Anti-Benchmark in the context of Risk Factor allocation.


Our aim is to illustrate that the Anti-Benchmark is evenly exposed to all the available sources of risk and also an appreciated diversifier relatively to the other Risk Factor Driven strategies.

### 1/ Even exposure to all available risk factors

TOBAM's "intelligent Beta" approach aims to go the distance in maximizing diversification from the outset. Other non-market capitalization approaches could be biased toward a single investment style and/or certain risk characteristics (low volatility stocks, value stocks, growth stocks...).

TOBAM's Anti-Benchmark approach is designed to capture the risk premium of an asset class evenly from all the independent risk factors available in the market at any given time, in other words, to explicitly avoid biases in terms of market cap, sector or style. The Anti-Benchmark does not identify risk factors; the even exposure to the sources of risk is an outcome of maximizing the Diversification Ratio (DR). The even exposure, being a result of maximizing diversification, is a unique property of the Anti-Benchmark.

For this reason, we apply as few constraints as possible, in order to avoid unwanted systematic exposures, and to ensure that the most diversified portfolio is free of style bias or other biases. Style analyses conducted by global consultants or independent risk analysis providers conclude that TOBAM's portfolios consistently display a "core" style profile.

- No factor bias in absolute terms  Even exposure to all risk factors as a result of maximizing the DR
- The Anti-Benchmark maximizes the number of independent effective sources of risk: Anti-Benchmark  $\Leftrightarrow$  Max DR (P)
 
$$\Leftrightarrow \text{Max } \frac{(w_1\sigma_1 + w_2\sigma_2 + \dots + w_n\sigma_n)}{\sigma_p}$$

$$\Leftrightarrow \text{Max number of independent effective sources of risk}$$
- In relative terms:
  - The cap-weighted benchmark builds concentrations or "bets," which are dynamic and do not result in wealth creation as they consist of adding to positions or "bets" that were successful in the past.
  - Other non-market capitalization approaches could be biased toward a single investment style and/or certain risk characteristics (low volatility stocks, value stocks, growth stocks...).

## 2/ Empirical illustrations (Fama French)

The above statement is completely sound even from a theoretical point of view, in the below we have shown some empirical illustrations.

### World Developed Region

Regression of the Anti-Benchmark excess returns vs. the MSCI World, the Value/Growth and Small/Large Factors (Dec 30, 1999 – Dec 31, 2013):

30/12/1999 - 31/12/2013	AB World		MSCI World	Small/Large	Value/Growth	Intercept
<b>AB World Annualized Excess Return</b>	<b>9.05%</b>	=	<b>2.78%</b>	<b>1.18%</b>	<b>0.21%</b>	<b>4.87%</b>
<b>Coefficients</b>			0.61	0.23	0.07	
Regression t-statistic			121.44	18.11	7.87	3.55
Level of significance			100.0%	100.0%	100.0%	100.0%

- o The Beta of 0.61 to the MSCI World Index and, the Fama-French factors' relative small contribution to the Anti-Benchmark excess return, indicates that the outperformance of the Anti-Benchmark is mostly explained by the intercept (the residual) and is therefore not only explained by common market factors or common investment styles.

### Emerging Markets Region

Regression of the Anti-Benchmark excess returns vs. the MSCI EM, the Value/Growth and Small/Large Factors (Dec 29, 2000- Dec 31, 2013, daily returns)

29/12/2000 - 31/12/2013	AB EM		MSCI EM	Small/Large	Value/Growth	Intercept
<b>AB EM Annualized Excess Return</b>	<b>16.01%</b>	=	<b>9.83%</b>	<b>1.63%</b>	<b>0.10%</b>	<b>4.45%</b>
<b>Coefficients</b>			0.76	0.28	-0.04	
Regression t-statistic			119.68	22.45	-1.55	2.40
Level of significance			100.0%	100.0%	87.9%	98.4%

Source: TOBAM.

- o Same as in developed markets, the intercept (what remains after the contribution of the common risk drivers) is the major contributor to the excess returns.

### **3/ Diversifying benefits of the Anti-Benchmark compared to the risk factor driven strategies**

#### **Methodology**

The purpose of this part is to analyze the benefits of the Anti-Benchmark in the context of risk factor decomposition. The study concludes that the Anti-Benchmark is an appreciated diversifier relatively to Risk Factor Driven strategies.

We analyze the relative risk/return characteristics of the AB and of a variety of MSCI Indices over a five years period (over a market cycle), split into two regions: Developed Markets and Emerging Markets.

In addition to the regional benchmark, the factors considered in the study are:

1. Growth
2. Value
3. Small capitalizations
4. Large capitalizations

This review illustrates the diversification benefits of the Anti-Benchmark which generally:

- provides a combination of return improvement and volatility reduction
- has the lowest pair-wise correlation among all portfolios
- has the highest pair-wise tracking error among all portfolios

In fact this analysis shows that the AB does what it says on the tin, achieving maximum diversification. The Most Diversified Portfolio (MDP) is by definition the non-diversifiable portfolio.

This means that:


- The MDP is a diversifier to other strategies
- The MDP as a result of maximizing diversification provides an even exposure to all risk factors available

## AB World versus single factors

We look at the period 31/12/2007 – 31/10/2013 using daily data. The indices used are:

- Growth: MSCI Daily TR Net Growth World
- Value : MSCI Daily TR Net Value World
- Small : MSCI Daily TR Net Small Cap World (proxy)
- Large : MSCI World Large Cap Net Total Return (proxy)
- Benchmark: MSCI World TR Net

Chart 1: Risk/Return profile of AB World and single factors



Source: Bloomberg, TOBAM

Table 1: pair-wise correlation and average tracking error, world region

Correlation	AB	BM	SMALL	LARGE	VALUE	GROWTH	Average	Avg Tracking Error
AB		92%	91%	92%	85%	87%	89%	12.3%
BM	92%		98%	99%	90%	91%	94%	7.9%
SMALL	91%	98%		95%	85%	87%	91%	9.6%
LARGE	92%	99%	95%		91%	92%	94%	8.2%
VALUE	85%	90%	85%	91%		96%	89%	12.5%
GROWTH	87%	91%	87%	92%	96%		91%	10.4%

Source: TOBAM

Chart 1 and table 1 show the efficiency of the Anti-Benchmark, which diversifying properties also stands out as having the lowest average correlation and second highest average tracking error to other strategies in the World Developed region.

## AB EM versus single factors

We look at the period 31/12/2007 – 31/10/2013 using daily data. The indices used are:

- Growth: MSCI Daily TR Net Growth EM
- Value : MSCI Daily TR Net Value EM
- Small : MSCI Daily TR Net Small Cap EM (proxy)
- Large : MSCI EM Large Cap Net Total Return (proxy)
- Benchmark: MSCI EM TR Net

Chart 2: Risk/Return profile of AB EM and single factors



Source: Bloomberg, TOBAM

Table 2: pair-wise correlation and average tracking error, EM region

Correlation	AB	BM	SMALL	LARGE	VALUE	GROWTH	Average	Avg Tracking Error
AB		91%	92%	87%	91%	91%	90%	11.5%
BM	91%		97%	98%	100%	100%	97%	5.4%
SMALL	92%	97%		93%	97%	97%	95%	7.8%
LARGE	87%	98%	93%		98%	98%	95%	9.0%
VALUE	91%	100%	97%	98%		99%	97%	6.1%
GROWTH	91%	100%	97%	98%	99%		97%	6.0%

Source: TOBAM

Chart 2 and table 2 show the efficiency of the Anti-Benchmark, which diversifying properties also stands out as having the lowest average correlation and highest average tracking error to other strategies in the Emerging Markets region

## For more information

TOBAM is an asset management company offering innovative investment capabilities whose aim is to maximize diversification. TOBAM's flagship Anti-Benchmark® strategies, supported by original research and a mathematical definition of diversification, provide clients with diversified core equity exposure, both globally and in domestic markets. The company manages over \$5.6 billion via its Anti-Benchmark strategies for institutional clients worldwide. Its team includes twenty four financial professionals.

## Contacts:

### Head of Business Development

Christophe Roehri

+33 1 53 23 41 60

[Christophe.Roehri@tobam.fr](mailto:Christophe.Roehri@tobam.fr)

### Business Development

Laura Vu Thien

+33 1 53 23 41 65

[Laura.VuThien@tobam.fr](mailto:Laura.VuThien@tobam.fr)

Fabien Jullia

+33 1 53 23 41 72

[Fabien.Jullia@tobam.fr](mailto:Fabien.Jullia@tobam.fr)

### Client Service

Joe Kiwan

+33 1 53 23 41 66

[ClientService@tobam.fr](mailto:ClientService@tobam.fr)

## Disclaimers

*This document is intended for professional investors only. This document is confidential and may not be reproduced in any form without the express permission of TOBAM and to the extent that it is passed on, care must be taken to ensure that any reproduction is in a form which accurately reflects the information presented here. While TOBAM believes that the information is correct at the date of production, no warranty or representation is given to this effect and no responsibility can be accepted by TOBAM to the recipient of this document or end users for any action taken on the basis of the information contained herein. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. No reliance may be placed for any purpose on the information and opinions contained in this document or their accuracy or completeness. Opinions expressed herein reflect the opinion of TOBAM and are subject to change without notice. This document is for information purposes and does not constitute advice or a recommendation to enter into any transaction or an offer or an agreement, or a solicitation of an offer or an agreement, to enter into any transaction, nor shall it or the fact of its distribution form the basis of, or be relied on in connection with, any contract for the same. The fund(s) that may be mentioned in this email or document may not be eligible for sale in some states or countries and they may not be suitable for all types of investors. Before entering into any transaction, you should consider the suitability of the transaction to your particular circumstances and independently review (with your professional advisers as necessary) the specific financial risks as well as the legal, regulatory, credit, tax and accounting consequences of entering into such transaction. The value and the income produced by a strategy may be adversely affected by exchange rates, interest rates, or other factors so that an investor may get back less than he or she invested. Past performance is not indicative of future results. TOBAM has continued and will continue its research efforts, amending the investment process from time to time accordingly. TOBAM reserves the right of revision or change without notice, of the universe, data, models, and strategy. **Copyrights:** All text, graphics, interfaces, logos and artwork, including but not limited to the design, structure, selection, coordination, expression, "look and feel" and arrangement contained in this presentation, are owned by TOBAM and are protected by copyright and various other intellectual property rights and unfair competition laws. **Trademarks:** "TOBAM," "MaxDiv," "Maximum Diversification," "Diversification Ratio," "Most Diversified Portfolio," "Most Diversified Portfolios," "MDP" and "Anti-Benchmark" are registered trademarks. The absence of a product or service name from this list does not constitute a waiver of TOBAM trademark or other intellectual property rights concerning that name.*

**Patents:** The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are patented or patent pending. **Knowledge, processes and strategies:** The Anti-Benchmark, MaxDiv and Maximum Diversification strategies, methods and systems for selecting and managing a portfolio of securities, processes and products are protected under unfair competition, passing-off and misappropriation laws.

**Terms of use:** TOBAM owns all rights to, title to and interest in TOBAM products and services, marketing and promotional materials, trademarks and Patents, including without limitation all associated Intellectual Property Rights. Any use of the intellectual property, knowledge, processes and strategies of TOBAM for any purpose and under any form (known and/or unknown) in direct or indirect relation with financial products including but not limited to certificates, indices, notes, bonds, OTC options, warrants, mutual funds, ETFs and insurance policies (i) is strictly prohibited without TOBAM's prior written consent and (ii) requires a license.

*This document is issued by TOBAM which is authorized and regulated by the Autorité des Marchés Financiers ("AMF"). © TOBAM 2013*